Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | IDE | P14735 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4794713 | 0.78 | MYC (0.52) | MYCALDH1A1MAPTTSHRSMN1; SMN2 | |
| SCHEMBL3418836 | 0.77 | ALDH1A1 (0.53) | MYCALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL3412053 | 0.76 | MYC (0.54) | MYCALDH1A1MAPTTSHRSMN1; SMN2 | |
| SCHEMBL28604415 | 0.76 | POLB (0.46) | ALDH1A1MAPTTSHRGAAMAPK1 | |
| SCHEMBL17784943 | 0.76 | MYC (0.53) | MYCALDH1A1MAPTTSHRSMN1; SMN2 | |
| Dimethyl Yellow SCHEMBL9446359 | 0.76 | MYC (0.79) | MYCALDH1A1MAPTTSHRSMN1; SMN2 | |
| Methyl Yellow SCHEMBL9446361 | 0.76 | MYC (0.79) | MYCALDH1A1MAPTTSHRSMN1; SMN2 | |
| SCHEMBL15240 | 0.75 | ALDH1A1 (0.72) | MYCALDH1A1MAPTTSHRSMN1; SMN2 | |
| Azobenzene SCHEMBL29009080 | 0.75 | ALDH1A1 (0.70) | MYCALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL133466 | 0.75 | TDP1 (0.43) | MYCALDH1A1MAPTTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4402123-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4402121-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118317944-A | Acyclic lipids and methods of use thereof | 雷纳嘉德医疗管理公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118234707-A | Cyclic lipids and methods of use thereof | 雷纳嘉德医疗管理公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2024-06-20 | — | — | US | disclosed |
| EP-1196623-B1 | METHOD FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISMS | FORENSIC SCIENCE SERVICE LTD (GB) | 2007-07-25 | — | — | EP | disclosed |
| CN-1948468-A | Hybridization immune deficiency virus strain and application | UNIV WUHAN (CN) | 2007-04-18 | — | — | CN | disclosed |
| US-20060099614-A1 | Analysis of DNA | THE SECRETARY OF STATE FOR THE HOME DEPARTMENT (GB) | 2006-05-11 | — | — | US | disclosed |
| US-20060003388-A1 | Sensitive intracellular calcium assay | EUROFINS DISCOVERX CORPORATION | 2006-01-05 | — | — | US | disclosed |
| CN-1638954-A | Color changing element for time indicating label and method of making and using same | AVERY DENNISON CORP (US) | 2005-07-13 | — | — | CN | disclosed |
| US-20030219422-A1 | Allosteric ribozymes and uses thereof | NOXXON PHARMA AG (DE) | 2003-11-27 | — | — | US | disclosed |
| US-20030138780-A1 | Investigating single fragment length polymorphisms (SNP) in nucleic acid sample; forensics; polymerase chain reactions; electrophoresis; colorimetric analysis | THE SECRETARY OF STATE FOR THE HOME DEPARTMENT (GB) | 2003-07-24 | — | — | US | disclosed |
| EP-1312674-A1 | Allosteric ribozymes and uses thereof | Noxxon Pharma AG (DE) | 2003-05-21 | — | — | EP | disclosed |
| EP-1196623-A2 | METHOD FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISMS | The Secretary of State for the Home Department (GB) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007640-A2 | METHOD FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISMS | THE SECRETARY OF STATE FOR THE HOME DEPARTMENT (GB) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | MYC 2760/4885ALDH1A1 4876/4885MAPT 3403/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | MYC 4413/4885ALDH1A1 4885/4885MAPT 2004/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | MYC 2760/4885ALDH1A1 4876/4885MAPT 3403/4885 |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | MYC 3067/4885ALDH1A1 4882/4885MAPT 4102/4885 |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | NSUN3, PHAX, RNGTT | MYC 1831/4885ALDH1A1 4735/4885MAPT 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.